Searching across hundreds of databases
Are you sure you want to leave this community? Leaving the community will revoke any permissions you have been granted in this community.
Integrated Clinical Trials is a virtual database currently indexing clinical trials from: EU Clinical Trials Register and ClinicalTrials.gov.
(last updated: Nov 28, 2022)
Clinical Trials Information| Database | Title | Recruitment | Conditions | Intervention | Sponsored By | Gender | |||||
|---|---|---|---|---|---|---|---|---|---|---|---|
Clinicaltrials.gov | SCALE KIDS: Research Study to Look at How Well a New Medicine is at Lowering Weight in Children With Obesity | Recruiting | Obesity | Drug, Drug - Liraglutide, Placebo | Novo Nordisk A/S, Industry | 6 Years - 12 Years | Phase 3 | Interventional | The study looks at how liraglutide works on participant's body weight. Researchers will look at how liraglutide can help children with obesity to lose weight. They will look at how much weight the children will lose, and if there are any side effects. Participants will either get liraglutide or placebo. Which treatment the participants get is decided by chance. Liraglutide is a new medicine for children, but it can already be prescribed by doctors to adults with overweight or obesity. The participant will get 1 injection every day. In addition to taking the medicine, the participants will have talks with the study staff about healthy food choices, how they can be more physically active and what can be done to help the participants to lose weight. The study will last for about 96 weeks (almost 2 years). The participants will have 18 clinic visits and 10 phone or video calls with the study doctor/staff. Participant will have blood samples taken, have 1 test to check the heart, 1 hand X-ray taken and must fill in a diary between some of the visits. | ||
|
Clinicaltrials.gov | Liraglutide for HIV-associated Neurocognitive Disorder | Suspended | HIV Infection, Diabetes Mellitus Type 2, Obesity, Overweight, Metabolic Syndrome | Drug - Liraglutide | Temple University, The Comprehensive NeuroAIDS Center (CNAC) at Temple University, Other, Other | 18 Years - 65 Years | Phase 4 | Interventional | This study will test the effect of liraglutide on cognitive function in HIV-infected overweight or obese subjects with type 2 diabetes. | ||
Clinicaltrials.gov | Effect of Liraglutide on Epicardial Fat in Subjects With Type 2 Diabetes | Completed | Type 2 Diabetes, Overweight, Obesity | Drug, Drug - Liraglutide, Metformin | University of Miami, Other | 18 Years - 65 Years | Phase 4 | Interventional | The purpose of this research study is to learn about the effect of Liraglutide, (Victoza®), on the fat surrounding the heart.Excessive amount of the fat around the heart is common in people with type 2 diabetes and can be associated with poor sugar control. Liraglutide is an injectable prescription medicine that can improve blood sugar control in adults with type 2 diabetes. | ||
|
Clinicaltrials.gov | In Market Utilisation of Liraglutide Used for Weight Management in the UK: a Study in the CPRD Primary Care Database | Enrolling by invitation | Obesity, Overweight | Drug - Liraglutide | Novo Nordisk A/S, Industry | N/A - N/A | Observational | This study is conducted in Europe. The aim of this study is to investigate the usage of liraglutide for weight management in clinical practice using the CPRD (Clinical Practice Research Datalink) primary care database. | |||
|
Clinicaltrials.gov | Cardiovascular Effects of GLP-1 Receptor Activation | Completed | Obesity, PreDiabetes | Drug, Drug, Other, Drug, Drug - Liraglutide, Sitagliptin, hypocaloric diet, Placebos, Exendin (9-39) | Vanderbilt University Medical Center, American Heart Association, Other, Other | 18 Years - 65 Years | Phase 4 | Interventional | This project tests the principle hypothesis that stable glucagon like peptide-1 (GLP-1) analogues have specific GLP1R-dependent beneficial effects on vascular endothelial function, fibrinolysis and inflammation in obesity that exceed the benefits of weight loss, and that genetic or other individual factors that modulate GLP1R sensitivity can modify the effect of these analogues on cardiovascular risk. | ||
|
Clinicaltrials.gov | Gut Microbiome Changes Following Liraglutide Treatment in Obese Subjects or Overweight Subjects With Co-morbidities | Recruiting | Obesity | Drug, Drug - Liraglutide, placebo | Xiangya Hospital of Central South University, Other | 18 Years - 75 Years | Phase 3 | Interventional | We performed a multicenter, randomized, double-blind, placebo-controlled 28-week trial. 300 non-diabetic obese subjects or overweight subjects with co-morbidities were randomly assigned. Eligible participants were randomized 2:1 to once-daily subcutaneous injections of either liraglutide or placebo. The primary outcome is to investigate the composition of the gut microbiota from baseline to end of treatment. | ||
|
Clinicaltrials.gov | A Regulatory Post-marketing Surveillance (rPMS) Study to Evaluate the Safety and Effectiveness of Saxenda®(Liraglutide 3.0 mg) in Obese Patients and Overweight Patients With Obesity-related Comorbidities in Routine Clinical Practice in Korea. | Completed | Obesity, Overweight | Drug - Liraglutide | Novo Nordisk A/S, Industry | 18 Years - N/A | Observational | The purpose of this study is to collect information about the safety and effectiveness of Saxenda® in obese patients and overweight patients with obesity-related comorbidities. The participant will attend the clinic or hospital according to usual practice and receive medical care, as agreed with the study doctor. The participation is expected to be approximately for 26 weeks. | |||
|
Clinicaltrials.gov | Effects of GLP-1 RAs on Weight and Metabolic Indicators in Obese Patients | Recruiting | Obesity | Drug, Drug, Drug - Liraglutide, Exenatide, Exenatide Microspheres for Injection | Xiangya Hospital of Central South University, Other | 18 Years - 65 Years | Phase 3 | Interventional | This studay evaluates the effect of the glucagon-like peptide-1 (GLP-1) receptor agonist,including Liraglutide,Exenatide and Exenatide Microspheres for Injection,in the treatment of subjects who are overweight or obese. | ||
|
Clinicaltrials.gov | Liraglutide (Saxenda(R)) in Adolescents With Obesity After Sleeve Gastrectomy | Recruiting | Obesity, Status Post Sleeve Gastrectomy | Drug - Liraglutide | Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD), NIH | 12 Years - 20 Years | Phase 2 | Interventional | Background: Metabolic Bariatric Surgery, including a surgery called vertical sleeve gastrectomy, is the most effective weight loss treatment for severe obesity. However, many adolescents who have this surgery still have obesity 1 year later or regain weight. Researchers want to see if a drug can help. Objective: To learn if liraglutide can help adolescents who still have obesity 1 year or more after vertical sleeve gastrectomy lose additional weight. Eligibility: Healthy adolescents ages 12-20.99 years who are 1-10 years post vertical sleeve gastrectomy and have a BMI of 30 kg/m2 or >=95th percentile for age and sex. Design: Participants will be screened with: Medical history Physical exam Questionnaires about their mood and feelings about their weight Blood and urine tests Nutrition counseling. They will keep a diet log. A test where they view and respond to pictures of food Wrist accelerometer set-up. They will wear an accelerometer (a device like a watch) on their wrist for 14 days. It will measure their physical activity. Some screening tests will be repeated during the study. Participants will have an oral glucose tolerance test. They will ingest a sweet liquid. Blood samples will be taken. Participants will take liraglutide daily for 16 weeks. They will learn how to inject it under their skin. Participants will have a body scan to measure muscle and fat. Participants will be invited to eat as much as they want at a buffet meal at NIH. How much food they eat will be calculated. They will assess their appetite and mood before and after the meal. Participation will last for 7 months. Participants will have 7 study visits.... | ||
|
Clinicaltrials.gov | The Effect and the Pharmacogenomics Study of Liraglutide in Obese Patients | Withdrawn | Obesity | Drug, Drug - Liraglutide, Liraglutide, metformin | Xiangya Hospital of Central South University, Other | 18 Years - 65 Years | Phase 2 | Interventional | This studay evaluates the effect of liraglutide in the treatment of obese patients ande the influence of genetic factors on the curative effect.Half of participants will receive Liraglutide alone,while the other half who can not achieving adequate glycaemic control will receive Liraglutide and metformin in combination. | ||
|
Clinicaltrials.gov | Pilot Study of the Effect of Liraglutide 3.0 mg on Weight Loss and Gastric Functions in Obesity | Completed | Obesity | Drug, Drug - Liraglutide, Placebo | Michael Camilleri, MD, National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), Novo Nordisk A/S, Other, NIH, Industry | 18 Years - 65 Years | Phase 2 | Interventional | This study is being done to assess the stomach emptying effect of a maximum dose of 3 mg Liraglutide compared to placebo in subjects who are overweight or obese. Liraglutide is a medication approved by the Food and Drug Administration (FDA) for routine clinical use. | ||
|
Clinicaltrials.gov | GLP-1 Response and Effect in Individuals With Obesity Causing Genetic Mutations | Completed | Obesity | Drug - Liraglutide | University of Copenhagen, Other | 18 Years - 65 Years | Phase 2 | Interventional | The obesity epidemic is attributable to dietary and behavioral trends acting on a person's genetic makeup to determine body mass and susceptibility to obesity-related diseases. Furthermore, common forms of obesity have a strong hereditary component and many genetic pathways that contribute to obesity have already ben identified. Glucagon-like peptide-1 (GLP-1) is an incretin hormone that potentiates glucose-stimulated insulin secretion. However, GLP-1 also acts as an appetite-inhibiting hormone affecting the appetite center in the hypothalamus. Today, GLP-1 receptor agonists are available for the treatment of type 2 diabetes, and their treatment potential in obesity is an area of active research. The aim of this study is to explore if the appetite inhibiting effect of GLP-1 is intact in people diagnosed with obesity causing genetic disorders and to investigate the physiological role of GLP-1 on food intake and appetite regulation in this group. | ||
|
Clinicaltrials.gov | Antigen-Lipid-Driven Monoclonal Gammopathies Targeting Epicardial Fat | Withdrawn | Monoclonal Gammopathies, Overweight, Obesity | Drug - Liraglutide | University of Miami, Other | 18 Years - 70 Years | Phase 4 | Interventional | The purpose of this research study is to learn about the effect of Liraglutide (Victoza) on the fat of the heart and some fat cells in blood. | ||
|
Clinicaltrials.gov | Efficacy and Safety of Liraglutide on Body Weight in Obese Subjects or Overweight Subjects With Co-morbidities | Recruiting | Obesity | Drug, Drug - Liraglutide, placebo | Xiangya Hospital of Central South University, Other | 18 Years - 75 Years | Phase 3 | Interventional | We performed a multicenter, randomized, double-blind, placebo-controlled 28-week trial. 300 non-diabetic obese subjects or overweight subjects with co-morbidities were randomly assigned. Eligible participants were randomized 2:1 to once-daily subcutaneous injections of either liraglutide or placebo. The primary outcome is to investigate the safety, tolerability from baseline to end of treatment. | ||
|
Clinicaltrials.gov | Effect of Liraglutide for Weight Management in Pubertal Adolescent Subjects With Obesity | Completed | Metabolism and Nutrition Disorder, Obesity | Drug, Drug - Liraglutide, Placebo | Novo Nordisk A/S, Industry | 12 Years - 17 Years | Phase 3 | Interventional | This trial is conducted globally. The aim of this trial is to investigate the effect of liraglutide for weight management in pubertal adolescent subjects with obesity. | ||
|
Clinicaltrials.gov | Pilot Study of the Effect of Liraglutide on Weight Loss and Gastric Functions in Obesity | Completed | Obesity | Drug, Drug - Liraglutide, Placebo | Mayo Clinic, National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), Novo Nordisk A/S, Other, NIH, Industry | 18 Years - 65 Years | Phase 2 | Interventional | This study was being done to assess the stomach emptying effect of a maximum dose of 3 mg Liraglutide compared to placebo in subjects who are overweight or obese. Liraglutide is a medication approved by the Food and Drug Administration (FDA) for routine clinical use. | ||
|
Clinicaltrials.gov | Adding Liraglutide to High Dose Insulin: Breaking the Cycle | Completed | Type 2 Diabetes Mellitus, Obesity | Drug, Drug - Liraglutide, Saline | Ildiko Lingvay, Novo Nordisk A/S, Other, Industry | 18 Years - N/A | Phase 4 | Interventional | The purpose of this study is to evaluate whether the addition of liraglutide 1.8 mg/day to a high-dose insulin regimen (>1.8 units/kg/day) in patients with uncontrolled (HbA1c >7.5%) type 2 diabetes mellitus will improve blood sugar control. It also evaluates the effect of liraglutide on liver and pancreatic fat content, explores the mechanism of blood sugar improvement by assessing weight and pancreatic hormone release, and assesses blood pressure, lipid profile, and liver function. Finally it will look at patient quality of life and safety. |
Welcome to the RRID Resources search. From here you can search through a compilation of resources used by RRID and see how data is organized within our community.
You are currently on the Community Resources tab looking through categories and sources that RRID has compiled. You can navigate through those categories from here or change to a different tab to execute your search through. Each tab gives a different perspective on data.
If you have an account on RRID then you can log in from here to get additional features in RRID such as Collections, Saved Searches, and managing Resources.
Here is the search term that is being executed, you can type in anything you want to search for. Some tips to help searching:
If you are logged into RRID you can add data records to your collections to create custom spreadsheets across multiple sources of data.
Here are the facets that you can filter the data by.
If you have any further questions please check out our FAQs Page to ask questions and see our tutorials. Click this button to view this tutorial again.
